{"id":"esperoct","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Factor VIII inhibition","drugRate":"30%","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"5.2%","severity":"common","organSystem":""},{"effect":"Injection site reaction","drugRate":"2.6%","severity":"common","organSystem":""},{"effect":"Drug hypersensitivity","drugRate":"2.5%","severity":"common","organSystem":""},{"effect":"Redness","drugRate":"1.9%","severity":"common","organSystem":""},{"effect":"Itching (pruritus)","drugRate":"1.5%","severity":"common","organSystem":""}],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Neutralizing antibodies to Factor VIII (Factor VIII inhibitor)","drugRate":"0.4%","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":["Turoctocog alfa pegol (N8-GP)"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"562f94e8-825f-4d7f-b93c-b783ac3a43bc","title":"ESPEROCT (ANTIHEMOPHILIC FACTOR (RECOMBINANT), GLYCOPEGYLATED-EXEI) KIT [NOVO NORDISK]"},"ecosystem":[],"mechanism":{},"_scrapedAt":"2026-03-28T01:52:00.272Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Hereditary factor VIII deficiency disease","diseaseId":"hereditary-factor-viii-deficiency-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06579144","phase":"PHASE1","title":"Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A","status":"RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2025-02-24","conditions":"Hemophilia A","enrollment":24},{"nctId":"NCT05082116","phase":"PHASE3","title":"Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-09-27","conditions":"Haemophilia A","enrollment":36},{"nctId":"NCT02137850","phase":"PHASE3","title":"Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-06-26","conditions":"Congenital Bleeding Disorder, Haemophilia A","enrollment":124},{"nctId":"NCT04574076","phase":"","title":"A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®","status":"ENROLLING_BY_INVITATION","sponsor":"Novo Nordisk A/S","startDate":"2020-10-23","conditions":"Haemophilia A","enrollment":60},{"nctId":"NCT04682145","phase":"","title":"Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol","status":"ENROLLING_BY_INVITATION","sponsor":"Novo Nordisk A/S","startDate":"2020-12-09","conditions":"Haemophilia A","enrollment":50},{"nctId":"NCT04334057","phase":"","title":"Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-03-31","conditions":"Haemophilia A","enrollment":23},{"nctId":"NCT05621746","phase":"","title":"An Observational Research Study of the Health of Joints in People With Haemophilia Taking the Medicine Esperoct","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2022-11-23","conditions":"Haemophilia A","enrollment":100},{"nctId":"NCT03528551","phase":"PHASE3","title":"A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-04-30","conditions":"Congenital Bleeding Disorder, Haemophilia A","enrollment":160},{"nctId":"NCT01480180","phase":"PHASE3","title":"Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-01-30","conditions":"Congenital Bleeding Disorder, Haemophilia A","enrollment":186},{"nctId":"NCT01731600","phase":"PHASE3","title":"A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-02-20","conditions":"Congenital Bleeding Disorder, Haemophilia A","enrollment":68},{"nctId":"NCT01489111","phase":"PHASE3","title":"Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-08-03","conditions":"Congenital Bleeding Disorder, Haemophilia A","enrollment":36},{"nctId":"NCT02994407","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-01-30","conditions":"Congenital Bleeding Disorder, Haemophilia A","enrollment":50},{"nctId":"NCT02920398","phase":"PHASE1","title":"A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-10-04","conditions":"Congenital Bleeding Disorder, Haemophilia A","enrollment":21},{"nctId":"NCT01205724","phase":"PHASE1","title":"Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-09","conditions":"Congenital Bleeding Disorder, Haemophilia A","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":14,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Esperoct","genericName":"Esperoct","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk-a-s","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}